Found 7 clinical trials
A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
- 0 views
- 25 Jun, 2025
- 4 locations
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
names of the study drugs involved in this study are:Iberdomide (a type of cereblon E3 ligase modulator)Elotuzumab (a type of monoclonal antibody)Dexamethasone (a type of
- 0 views
- 03 Jul, 2025
- 1 location
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (SINE)
This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does
- 0 views
- 06 May, 2025
- 1 location
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have
- 0 views
- 03 Jul, 2025
- 1 location
ATRA and Carfilzomib in Plasma Cell Myeloma Patients (ATRA)
proteasome inhibitor toxicity. Carfilzomib, a modified peptide epoxyketone that selectively targets intracellular proteasome enzymes, is approved in combination with dexamethasone in patients that have
- 0 views
- 25 Jun, 2025
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the
- 0 views
- 03 Jul, 2025
- 26 locations
A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma
Primary Objectives: Safety run-in: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk
- 0 views
- 03 Jul, 2025
- 9 locations